Applications

1508 – Pembrolizumab (MK-3475) in Mismatch Repair Deficient (dMMR) Stage IV Solid tumours other than colorectal cancer

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status -
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Pending

Application details

Reason for application

Amendment to MBS item.

Service or technology in this application

The proposed medical service is an ImmunoHistoChemistry (IHC) test for identification of dMMR for access to pembrolizumab in patients with metastatic or unresectable solid tumours other than colorectal cancers.

Type: Investigative

Medical condition this application addresses

Patients with unresectable or metastatic solid tumours other than colorectal cancer which are mismatch repair deficient (dMMR) who have progressed following prior treatment

Application documents

Application form

Consultation survey

PICO confirmation

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Meetings to consider this application

  • PASC meeting: 7 - 8 December 2017
  • ESC meeting: -
  • MSAC meeting: -